FDA Panel Shoots Down Cytokinetics  Bid for Second Heart Drug Approval
Regulation
FDA Panel Shoots Down Cytokinetics Bid for Second Heart Drug Approval
2022-12-14 18:51:57
by TWN Staff

WASHINGTON — A panel of advisors to the Food and Drug Administration on Tuesday declined to recommend approval of a new heart drug created by biotech firm Cytokinetics, finding the benefits of the drug do not outweigh its risks. The... Read More

Straight From The Well
scroll top